Mazankowski Alberta Heart Institute, University of Alberta Hospital, Edmonton, Alberta, Canada.
Am J Crit Care. 2012 Mar;21(2):89-98. doi: 10.4037/ajcc2012163.
Peripartum cardiomyopathy, a type of dilated cardiomyopathy of unknown origin, occurs in previously healthy women in the final month of pregnancy and up to 5 months after delivery. Although the incidence is low-less than 0.1% of pregnancies -morbidity and mortality rates are high at 5% to 32%. The outcome of peripartum cardiomyopathy is also highly variable. For some women, the clinical and echocardiographic status improves and sometimes returns to normal, whereas for others, the disease progresses to severe cardiac failure and even sudden cardiac death. In acute care, treatment may involve the use of intravenous vasodilators, inotropic medications, an intra-aortic balloon pump, ventricular-assist devices, and/or extracorporeal membrane oxygenation. Survivors of peripartum cardiomyopathy often recover from left ventricular dysfunction; however, they may be at risk for recurrence of heart failure and death in subsequent pregnancies. Women with chronic left ventricular dysfunction should be managed according to guidelines of the American College of Cardiology Foundation and the American Heart Association.
围生期心肌病，一种病因不明的扩张型心肌病，发生于妊娠最后 1 个月及分娩后 5 个月内的既往健康女性。尽管发病率较低（<0.1%的妊娠），但发病率和死亡率较高，为 5%至 32%。围生期心肌病的结局也高度可变。对于一些女性，临床和超声心动图状态改善，有时甚至恢复正常，而对于另一些女性，疾病进展为严重心力衰竭，甚至心源性猝死。在急性护理中，治疗可能涉及使用静脉血管扩张剂、正性肌力药物、主动脉内球囊泵、心室辅助装置和/或体外膜氧合。围生期心肌病的幸存者通常从左心室功能障碍中恢复；然而，她们在随后的妊娠中可能有心力衰竭和死亡复发的风险。患有慢性左心室功能障碍的女性应根据美国心脏病学会基金会和美国心脏协会的指南进行管理。
